DK2334326T3 - Mimotoper af alfa-synuklein og vacciner deraf til behandlingen af neurodegenerative forstyrrelser - Google Patents
Mimotoper af alfa-synuklein og vacciner deraf til behandlingen af neurodegenerative forstyrrelser Download PDFInfo
- Publication number
- DK2334326T3 DK2334326T3 DK09712380.6T DK09712380T DK2334326T3 DK 2334326 T3 DK2334326 T3 DK 2334326T3 DK 09712380 T DK09712380 T DK 09712380T DK 2334326 T3 DK2334326 T3 DK 2334326T3
- Authority
- DK
- Denmark
- Prior art keywords
- peptide
- synuclein
- alpha
- compound
- artificial
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Marine Sciences & Fisheries (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (11)
1. Mindst én forbindelse omfattende et peptid der har aminosyresekvensen valgt fra gruppen bestående af CDQPVLPD, CDMPVLPD, CDSPVLPD, CDQPVLPDN, CDMPVLPDN, CDSPVLPDN, CHDRPVTPD, CDRPVTPD, CDVPVLPD, CDTPVYPD, CDTPVIPD, CHDRPVTPDN, CDRPVTPDN, CDVPVLPDN, CDTPVYPDN, CDQPVLPDG, CDMPVLPDG, CDSPVLPDG, CDHPVHPDS, CDMPVSPDR, CDRPVYPDI, CDHPVTPDR, CDTPVLPDS, CDMPVTPDT, CDAPVTPDT, CDSPVVPDN, CDLPVTPDR, CDSPVHPDT, CDAPVRPDS, CDMPVWPDG, CDRPVQPDR, CYDRPVQPDR, CDMPVDADN, DQPVLPDC og DMPVLPDC, til anvendelse til forebyggelse og/eller behandling af synukleinopatier.
2. Forbindelse til anvendelse ifølge krav 1, kendetegnet ved at peptidet omfatter ved dets N- og/eller C-terminus en acetyleret aminosyrerest eller cystein (C).
3. Forbindelse til anvendelse ifølge krav 1 eller 2, kendetegnet ved at synukleinopatien er valgt fra gruppen bestående af Lewy Body-forstyrrelser (LBDs), fortrinsvis Parkinson's sygdom (PD), Parkison's sygdom med demens (PDD) og demens med Lewy Bodies (DLB), såvel som multipel system atrofi (MSA) eller neurodegeneration med hjerne jern akkumulation type I (NBIAType I)·
4. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 3, kendetegnet ved at forbindelsen er koblet til en farmaceutisk acceptabel bærer, fortrinsvis KLH (Keyhole Limpet Hemocyanin).
5. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 4, kendetegnet ved at forbindelsen er formuleret til intravenøs, subkutan, intradermal eller intramuskulær administration.
6. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 5, kendetegnet ved at forbindelsen er formuleret med en adjuvans, fortrinsvis aluminiumhydroxid.
7. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 6, kendetegnet ved at forbindelsen er indeholdt i medikamentet i en mængde på fra 0,1 ng til 10 mg, fortrinsvis 10 ng til 1 mg, især 100 ng til 100 pg.
8. Peptid med en aminosyresekvens valgt fra gruppen bestående af CDQPVLPD, CDMPVLPD, CDSPVLPD, CDQPVLPDN, CDMPVLPDN, CDSPVLPDN, CHDRPVTPD, CDRPVTPD, CDVPVLPD, CDTPVYPD, CDTPVIPD, CHDRPVTPDN, CDRPVTPDN, CDVPVLPDN, CDTPVYPDN, CDQPVLPDG, CDMPVLPDG, CDSPVLPDG, CDHPVHPDS, CDMPVSPDR, CDRPVYPDI, CDHPVTPDR, CDTPVLPDS, CDMPVTPDT, CDAPVTPDT, CDSPVVPDN, CDLPVTPDR, CDSPVHPDT, CDAPVRPDS, CDMPVWPDG, CDRPVQPDR, CYDRPVQPDR, CDMPVDADN, DQPVLPDC, og DMPVLPDC.
9. Peptid ifølge krav 8, kendetegnet ved at peptidet er koblet til en farmaceutisk acceptabel bærer, fortrinsvis KLH (Keyhole Limpet Hemocyanin).
10. Farmaceutisk formulering omfattende mindst ét peptid ifølge krav 8 eller 9.
11. Farmaceutisk formulering ifølge krav 10 til anvendelse som en vaccine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0029708A AT506535B1 (de) | 2008-02-22 | 2008-02-22 | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
PCT/AT2009/000071 WO2009103105A2 (en) | 2008-02-22 | 2009-02-23 | Mimotope |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2334326T3 true DK2334326T3 (da) | 2015-10-19 |
Family
ID=40933571
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15173612.1T DK2946790T3 (da) | 2008-02-22 | 2009-02-23 | Mimotoper af alfa-synuklein og vacciner deraf til behandlingen af neurodegenerative forstyrrelser |
DK09712380.6T DK2334326T3 (da) | 2008-02-22 | 2009-02-23 | Mimotoper af alfa-synuklein og vacciner deraf til behandlingen af neurodegenerative forstyrrelser |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15173612.1T DK2946790T3 (da) | 2008-02-22 | 2009-02-23 | Mimotoper af alfa-synuklein og vacciner deraf til behandlingen af neurodegenerative forstyrrelser |
Country Status (20)
Country | Link |
---|---|
US (4) | US9724399B2 (da) |
EP (3) | EP3388074B1 (da) |
JP (4) | JP5804707B2 (da) |
KR (1) | KR101627763B1 (da) |
CN (4) | CN107261133A (da) |
AT (1) | AT506535B1 (da) |
AU (1) | AU2009217216B2 (da) |
BR (1) | BRPI0908097A2 (da) |
CA (1) | CA2716007C (da) |
CY (2) | CY1116841T1 (da) |
DK (2) | DK2946790T3 (da) |
ES (3) | ES2688118T3 (da) |
HK (2) | HK1214769A1 (da) |
HR (2) | HRP20151148T1 (da) |
HU (2) | HUE039860T2 (da) |
LT (1) | LT2946790T (da) |
PL (2) | PL2334326T3 (da) |
PT (2) | PT2334326E (da) |
SI (2) | SI2946790T1 (da) |
WO (1) | WO2009103105A2 (da) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007120834A2 (en) | 2006-04-13 | 2007-10-25 | Peptimmune, Inc. | Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability |
EP2586460A1 (en) | 2007-10-16 | 2013-05-01 | Peptimmune, Inc. | Method for designing and preparing vaccines comprising directed sequence polymer composition via the directed expansion of epitopes |
AT506535B1 (de) | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
US8546532B2 (en) | 2008-04-17 | 2013-10-01 | Declion Pharmaceuticals, Inc. | Synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders |
US8940276B2 (en) | 2008-12-19 | 2015-01-27 | Biogen Idec International Neuroscience Gmbh | Human anti-alpha-synuclein antibodies |
PT2723379T (pt) * | 2011-06-23 | 2018-11-14 | Univ Of Zuerich | Moléculas de ligação anti-alfa-sinucleína |
SI2579042T1 (sl) | 2011-10-04 | 2014-09-30 | Affiris Ag | Postopek za detektiranje Ass-specifičnih protiteles v biološkem vzorcu |
CA2863953A1 (en) * | 2012-01-27 | 2013-08-01 | Neotope Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
EP2659906A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
EP2659907A1 (en) * | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
CN111499742B (zh) * | 2013-11-21 | 2024-05-07 | 豪夫迈·罗氏有限公司 | 抗-α-突触核蛋白抗体及使用方法 |
WO2016005545A1 (en) * | 2014-07-10 | 2016-01-14 | Affiris Ag | Substances and methods for the use in prevention and/or treatment in huntington's disease |
JP6684524B2 (ja) * | 2015-03-09 | 2020-04-22 | イミューン モジュレーション,インク. | 神経変性疾患の処置または予防のためのハイポエストキシド、その誘導体、関連化合物、およびアゴニスト |
AU2016348610B2 (en) * | 2015-11-03 | 2023-08-31 | Ac Immune Sa | Method for vaccination against a self-antigen in a human patient |
WO2018005867A2 (en) * | 2016-06-29 | 2018-01-04 | The Regents Of The University Of California | Structure-based peptide inhibitors of alpha-synuclein aggregation |
TWI644673B (zh) * | 2017-07-27 | 2018-12-21 | 百朗克股份有限公司 | 頭孢曲松的用途 |
IL300364A (en) | 2020-08-04 | 2023-04-01 | Ac Immune Sa | immunogenic substances |
EP4357354A1 (en) | 2021-06-18 | 2024-04-24 | Sumitomo Pharma Co., Ltd. | Epitope peptide of human alpha-synuclein and pharmaceutical composition including said peptide |
WO2023152260A1 (en) | 2022-02-09 | 2023-08-17 | Ac Immune Sa | Anti-alpha-synuclein therapeutic vaccines |
WO2023161526A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
WO2023161527A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
AT525943A2 (de) * | 2022-02-28 | 2023-09-15 | Tridem Bioscience Gmbh & Co Kg | Konjugat bestehend aus oder umfassend zumindest ein ß-Glucan oder ein Mannan |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030170229A1 (en) * | 1999-02-25 | 2003-09-11 | Smithkline Beecham Biologicals S.A. | Vaccine |
US7834146B2 (en) * | 2000-05-08 | 2010-11-16 | Monsanto Technology Llc | Recombinant polypeptides associated with plants |
US8106174B2 (en) * | 2000-05-08 | 2012-01-31 | Monsanto Technology Llc | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
WO2002094867A2 (fr) * | 2001-02-07 | 2002-11-28 | Institut Pasteur | Sequence du genome de photorhabdus luminescens souche tto1 et utilisations |
JP4863341B2 (ja) * | 2001-09-06 | 2012-01-25 | Meiji Seikaファルマ株式会社 | ヒラメラブドウイルス感染魚類用dnaワクチン |
WO2003045128A2 (en) | 2001-11-21 | 2003-06-05 | New York University | SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID β, PRION PROTEIN, AMYLIN, α-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO |
GB0216972D0 (en) * | 2002-07-22 | 2002-08-28 | Univ Lancaster | Peptides and peptide derivaties for the treatment of &-synuclein-related diseases |
US9034337B2 (en) * | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
US8506959B2 (en) * | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
TW200509968A (en) * | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US20080014194A1 (en) * | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
WO2004089369A2 (en) * | 2003-04-11 | 2004-10-21 | Cambridge University Technical Services Limited | Methods and means for treating protein conformational disorders |
US7358331B2 (en) * | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
EP2361928B1 (en) | 2003-05-19 | 2017-04-26 | Prothena Biosciences Limited | Truncated fragments of alpha-synuclein in Lewy body disease |
US20070213253A1 (en) | 2003-06-22 | 2007-09-13 | Koji Sode | Synuclein Mutant Having Aggregation-Inhibitory Activity |
EP2186518A1 (en) * | 2004-11-17 | 2010-05-19 | McLaurin, Joanne | Composition and methods for treatment of disorders of protein aggregation |
CN101142482A (zh) * | 2005-02-25 | 2008-03-12 | 阿拉巴马大学董事会 | 蛋白错误折叠和聚集的调节因子及其使用方法 |
CA2598792A1 (en) * | 2005-03-02 | 2006-09-08 | Metanomics Gmbh | Process for the production of fine chemicals |
CA2607651A1 (en) * | 2005-05-18 | 2007-04-19 | Maxygen, Inc. | Evolved interferon-alpha polypeptides |
JP2009523815A (ja) * | 2006-01-19 | 2009-06-25 | アンブルックス,インコーポレイテッド | 免疫原性が調節された非天然アミノ酸ポリペプチド |
WO2007129221A2 (en) * | 2006-02-17 | 2007-11-15 | Waratah Parmaceuticals Inc | Compositions comprising an epi-inositol compounds and methods for treatment of disorders of protein aggregation |
US20070197452A1 (en) * | 2006-02-17 | 2007-08-23 | Mclaurin Joanne | Treatment of amyloid-related diseases |
JP2010510254A (ja) * | 2006-11-24 | 2010-04-02 | ワラタ ファーマシューティカルズ, インコーポレイテッド | アルツハイマー病および関連の神経変性疾患のための併用処置 |
US20120142902A1 (en) * | 2007-02-23 | 2012-06-07 | The Regents Of The University Of California | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
US8147833B2 (en) * | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
DK3067066T3 (da) * | 2007-02-23 | 2019-05-20 | Prothena Biosciences Ltd | Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom |
AT505574B1 (de) * | 2007-08-10 | 2009-09-15 | Affiris Forschungs & Entwicklungs Gmbh | Mimotope zur behandlung von atherosklerose |
AT506535B1 (de) * | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
US8343497B2 (en) * | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
-
2008
- 2008-02-22 AT AT0029708A patent/AT506535B1/de not_active IP Right Cessation
-
2009
- 2009-02-23 CN CN201710228381.2A patent/CN107261133A/zh active Pending
- 2009-02-23 CN CN200980105866.6A patent/CN101969989B/zh active Active
- 2009-02-23 LT LTEP15173612.1T patent/LT2946790T/lt unknown
- 2009-02-23 CN CN201510561387.2A patent/CN105250999B/zh active Active
- 2009-02-23 HU HUE15173612A patent/HUE039860T2/hu unknown
- 2009-02-23 PT PT97123806T patent/PT2334326E/pt unknown
- 2009-02-23 KR KR1020107019372A patent/KR101627763B1/ko active IP Right Grant
- 2009-02-23 PT PT15173612T patent/PT2946790T/pt unknown
- 2009-02-23 JP JP2010547001A patent/JP5804707B2/ja active Active
- 2009-02-23 PL PL09712380T patent/PL2334326T3/pl unknown
- 2009-02-23 EP EP18173825.3A patent/EP3388074B1/en active Active
- 2009-02-23 EP EP09712380.6A patent/EP2334326B1/en active Active
- 2009-02-23 DK DK15173612.1T patent/DK2946790T3/da active
- 2009-02-23 AU AU2009217216A patent/AU2009217216B2/en active Active
- 2009-02-23 CN CN202211233768.4A patent/CN116327905A/zh active Pending
- 2009-02-23 HU HUE09712380A patent/HUE025963T2/en unknown
- 2009-02-23 PL PL15173612T patent/PL2946790T3/pl unknown
- 2009-02-23 ES ES15173612.1T patent/ES2688118T3/es active Active
- 2009-02-23 ES ES18173825T patent/ES2962346T3/es active Active
- 2009-02-23 ES ES09712380.6T patent/ES2550781T3/es active Active
- 2009-02-23 WO PCT/AT2009/000071 patent/WO2009103105A2/en active Application Filing
- 2009-02-23 BR BRPI0908097A patent/BRPI0908097A2/pt not_active Application Discontinuation
- 2009-02-23 SI SI200931880T patent/SI2946790T1/sl unknown
- 2009-02-23 SI SI200931295T patent/SI2334326T1/sl unknown
- 2009-02-23 US US12/918,077 patent/US9724399B2/en active Active
- 2009-02-23 CA CA2716007A patent/CA2716007C/en active Active
- 2009-02-23 DK DK09712380.6T patent/DK2334326T3/da active
- 2009-02-23 EP EP15173612.1A patent/EP2946790B1/en active Active
-
2014
- 2014-05-23 JP JP2014107332A patent/JP2014177483A/ja active Pending
-
2015
- 2015-10-21 CY CY20151100940T patent/CY1116841T1/el unknown
- 2015-10-29 HR HRP20151148TT patent/HRP20151148T1/hr unknown
-
2016
- 2016-03-11 HK HK16102825.9A patent/HK1214769A1/zh unknown
- 2016-07-07 JP JP2016135134A patent/JP6410764B2/ja active Active
- 2016-12-12 US US15/375,234 patent/US10517935B2/en active Active
-
2018
- 2018-04-13 HK HK18104829.9A patent/HK1245136A1/zh unknown
- 2018-06-12 JP JP2018111725A patent/JP2018154650A/ja active Pending
- 2018-09-24 HR HRP20181512TT patent/HRP20181512T1/hr unknown
- 2018-09-28 CY CY181101007T patent/CY1120709T1/el unknown
-
2019
- 2019-12-11 US US16/709,999 patent/US11534484B2/en active Active
-
2022
- 2022-11-21 US US18/057,273 patent/US20230201320A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11534484B2 (en) | Mimotopes of alpha-synuclein and vaccines thereof for the treatment of synucleinopathy | |
DK2467153T3 (da) | Anvendelse af mimotoper af alfa-synucleinepitoper til behandling af lewy body-sygdomme |